Biohaven Ltd
BHVN
Company Profile
Business description
Biohaven Ltd is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of life-changing treatments in key therapeutic areas, including immunology, neuroscience, and oncology. Its product pipeline includes Glutamate, Myostatin, Ion channels, Inflammation & Immunology, and Oncology. The company's products target diseases such as neuromuscular and metabolic diseases, antibody-drug conjugates for cancer, obsessive-compulsive disorder, and others.
Contact
c/o Biohaven Pharmaceuticals, Inc
215 Church Street
New HavenCT06510
USAT: +1 203 404-0410
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
256
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,626.20 | 52.80 | 0.62% |
| CAC 40 | 7,942.42 | 58.79 | 0.75% |
| DAX 40 | 24,036.11 | 101.13 | 0.42% |
| Dow JONES (US) | 42,677.24 | 114.83 | -0.27% |
| FTSE 100 | 8,781.12 | 81.81 | 0.94% |
| HKSE | 23,792.11 | 110.63 | 0.47% |
| NASDAQ | 19,142.71 | 72.75 | -0.38% |
| Nikkei 225 | 37,454.14 | 75.35 | -0.20% |
| NZX 50 Index | 12,699.61 | 55.38 | 0.44% |
| S&P 500 | 5,940.46 | 23.14 | -0.39% |
| S&P/ASX 200 | 8,401.90 | 58.60 | 0.70% |
| SSE Composite Index | 3,393.49 | 13.02 | 0.39% |